Overview

Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors

Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, dose escalation study of MNK-010 in subjects with advanced solid malignancies who have failed conventional therapy. The safety, tolerability, pharmacokinetic (PK) profile, and preliminary antitumor activity of ascending doses of MNK-010 will be evaluated in subjects with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Mallinckrodt